Bretisilocin

N/A

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameBretisilocin
Drug Alias NameGM-2505
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor agonistsGlutamate [NMDA] receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorGlutamate [NMDA] receptor
Therapy Area/IndicationsDepressive Disorder, MajorDepressive Disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGilgamesh Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie IncGilgamesh Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, MajorDepressive Disorder
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A